An observational post-authorization study to assess the effectiveness of a single dose Ad26.COV2.S for the prevention of COVID-19 using real-world data

This population-representative cohort study in U.S. clinical practice showed that a single dose of Ad26.COV2.S is effective for at least 12 months against several COVID-19 related outcomes. Individuals who were vaccinated with a single dose of Ad26.COV2.S were at lower risk for developing COVID-19, for being hospitalized for COVID-19, and for all-cause mortality temporally associated with COVID-19 compared to unvaccinated individuals in the U.S. during Alpha, Delta, and Omicron BA.1, BA.2, BA.212.1, and BA.5 variants circulation.

Authors

Institutions

Publication Details

Journal
Frontiers in Public Health
Published
2024-12-04
DOI
https://doi.org/10.3389/fpubh.2024.1501919
Citations
1
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

An observational post-authorization study to assess the effectiveness of a single dose Ad26.COV2.S for the prevention of COVID-19 using real-world data

Michael Batech, Ann M. Madsen, Amelia K. Boehme, Lexie Rubens et al.
1 citations
Frontiers in Public Health
SARS-CoV-2 and COVID-19 Research
0.39
article

An observational post-authorization study to assess the effectiveness of a single dose Ad26.COV2.S for the prevention of COVID-19 using real-world data

Michael Batech, Ann M. Madsen, Amelia K. Boehme, Lexie Rubens, Raymond A. Harvey, Deborah Ricci, Mawuli Nyaku, Astra Toyip
article en
1 citations

Abstract

This population-representative cohort study in U.S. clinical practice showed that a single dose of Ad26.COV2.S is effective for at least 12 months against several COVID-19 related outcomes. Individuals who were vaccinated with a single dose of Ad26.COV2.S were at lower risk for developing COVID-19, for being hospitalized for COVID-19, and for all-cause mortality temporally associated with COVID-19 compared to unvaccinated individuals in the U.S. during Alpha, Delta, and Omicron BA.1, BA.2, BA.212.1, and BA.5 variants circulation.

Frontiers in Public HealthVol. 12
Johnson & Johnson (United States) (US), Aetion (United States) (US)
Good health and well-being
Openalex Percentile: Top 34%
SARS-CoV-2 and COVID-19 Research
0.39
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

An observational post-authorization study to assess the effectiveness of a single dose Ad26.COV2.S for the prevention of COVID-19 using real-world data — Michael Batech, Ann M. Madsen, et al. · Frontiers in Public Health (2024) | TGRS Research Map | TGRS